昆藥集團(600422.SH):阿法骨化醇軟膠囊擬中標第五批國家組織藥品集採
格隆匯6月23日丨昆藥集團(600422.SH)公吿,2021年6月23日,公司的全資子公司昆明貝克諾頓製藥有限公司(“貝克諾頓”)參加了國家組織藥品聯合採購辦公室組織的第五批全國藥品集中帶量採購的投標工作。貝克諾頓進口分裝的原研參比製劑阿法骨化醇軟膠囊(“擬中選產品”)擬中選本次集中採購。
該產品適用於骨質疏鬆症;腎性骨病(腎病性佝僂病);甲狀旁腺機能亢進(伴有骨病者);甲狀旁腺機能減退;營養和吸收障礙引起的佝僂病和骨軟化症;假性缺鈣(D-依賴性I)的佝僂病和骨軟化症。
貝克諾頓擬中選產品於2018年12月25日被國家藥品監督管理局列入仿製藥參比製劑目錄(第十九批)(詳見公司公吿2019-002號)。擬中選產品2020年銷售收入約為2.034億元,佔公司2020年營業收入的2.64%。
本次集中採購是國家組織的第五批藥品集中帶量採購,採購週期中,醫療機構將優先使用本次藥品集中採購中選藥品,並確保完成約定採購量。若本次擬中選產品確定中選、簽訂採購合同並順利實施相關工作,將有助於進一步擴大產品的銷售規模,提高公司骨科產品的市場佔有率,提升公司品牌影響力,對公司的未來經營業績具有積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.